Table 1.
Drug Name | 2D Structure | AutoDock Vina Score (Energy) | Rosetta’s Energy Score (REU) | Clinical Stage | ||
---|---|---|---|---|---|---|
Hesperidin | −10.30 | −1502.39 | Phase 3/ Approved | |||
Rebastinib | −10.20 | −1498.69 | Phase 2 | |||
Losulazine | −10.27 | −1497.67 | Phase 0 | |||
Cep-32496 | −10.20 | −1497.02 | Phase 1 | |||
R428 | −10.40 | −1495.17 | Phase 2 | |||
Entrectinib | −10.57 | −1494.42 | Approved | |||
Osi-027 | −10.50 | −1492.85 | Phase 1 | |||
MK3207 | −10.97 | −1491.61 | Phase 2 | |||
Rimegepant | −10.77 | −1486.36 | Approved | |||
Bolazine | −10.47 | −1484.41 |
Note: For the drugs with multiple stereoisomers in MTiOpenScreen database, only one stereoisomer with the highest AutoDock Vina Score was listed.